Heat Biologics Stock Forecast, Price & News

-1.96 (-20.42 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.26 million shs
Average Volume1.96 million shs
Market Capitalization$192.91 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Heat Biologics and its competitors with MarketBeat's FREE daily newsletter.

Heat Biologics logo

About Heat Biologics

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.43 out of 5 stars

Medical Sector

872nd out of 2,099 stocks

Pharmaceutical Preparations Industry

421st out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

Is Heat Biologics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heat Biologics stock.
View analyst ratings for Heat Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than Heat Biologics?

Wall Street analysts have given Heat Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heat Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Heat Biologics

How were Heat Biologics' earnings last quarter?

Heat Biologics, Inc. (NASDAQ:HTBX) posted its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.02. The biopharmaceutical company earned $0.54 million during the quarter, compared to analysts' expectations of $0.57 million. Heat Biologics had a negative net margin of 1,055.71% and a negative trailing twelve-month return on equity of 26.09%.
View Heat Biologics' earnings history

How has Heat Biologics' stock been impacted by COVID-19 (Coronavirus)?

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HTBX stock has increased by 991.4% and is now trading at $7.64.
View which stocks have been most impacted by COVID-19

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for HTBX?

4 equities research analysts have issued 12 month target prices for Heat Biologics' stock. Their forecasts range from $4.00 to $32.00. On average, they anticipate Heat Biologics' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price.
View analysts' price targets for Heat Biologics
or view top-rated stocks among Wall Street analysts.

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the following people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 58, Pay $808.23k)
  • Mr. William L. Ostrander, CFO & Sec. (Age 53, Pay $230.62k)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS, Chief Medical Advisor
  • Dr. Anthony M. Manning, Chief Scientific Advisor (Age 59)

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.90%), Geode Capital Management LLC (0.76%), Principal Financial Group Inc. (0.60%), Principal Financial Group Inc. (0.60%), IndexIQ Advisors LLC (0.23%) and HRT Financial LP (0.18%). Company insiders that own Heat Biologics stock include Edward B Smith III and John K A Prendergast.
View institutional ownership trends for Heat Biologics

Which major investors are selling Heat Biologics stock?

HTBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Los Angeles Capital Management LLC, and HRT Financial LP. Company insiders that have sold Heat Biologics company stock in the last year include Edward B Smith III, and John K A Prendergast.
View insider buying and selling activity for Heat Biologics
or view top insider-selling stocks.

Which major investors are buying Heat Biologics stock?

HTBX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., IndexIQ Advisors LLC, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Sigma Planning Corp, Trexquant Investment LP, Virtu Financial LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Heat Biologics
or or view top insider-buying stocks.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $7.64.

How much money does Heat Biologics make?

Heat Biologics has a market capitalization of $192.91 million and generates $2.95 million in revenue each year.

How many employees does Heat Biologics have?

Heat Biologics employs 39 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is

Where are Heat Biologics' headquarters?

Heat Biologics is headquartered at 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.